Defymed's mission is to develop innovative medical devices for diabetic patients providing effective treatments and improving quality of life
million diabetics worldwide forecasted for 2045
billion per year spent on diabetes-related expenses
more than 10
million diabetics receiving insulin therapy have poorly regulated blood glucose levels
February 13 2018
Strasbourg, France, February 2018 – French-based Medtech company Defymed confirms its global position. Recognized by its peers for the development of two innovative medical devices – ExOlin®, an insulin delivery device, and MailPan®, a bioartificial pancreas – the company intends to strengthen its position as a worldwide leader in innovative phys...
February 05 2018
Vienna, February 14-17th 2018: We are happy to announce that Defymed won the “Startup Grant for the...